Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Arqule Inc (ARQL) Comm Stk US$.01

Sell:$19.99 Buy:$20.00 Change: $0.20 (0.99%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Change: $0.20 (0.99%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Change: $0.20 (0.99%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

Contact details

1 Wall St Fl 6
United States
+1 (781) 9940300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.44 billion
Shares in issue:
120.73 million
United States
US dollar

Key personnel

  • Patrick Zenner
    Independent Chairman of the Board
  • Peter Lawrence
    President, Chief Operating Officer
  • Paolo Pucci
    Chief Executive Officer, Director
  • Marc Schegerin
    Chief Financial Officer
  • Brian Schwartz
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.